Vimarsana
Biggest News Aggregation in the World

James Loerop News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from James Loerop. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In James Loerop Today - Breaking & Trending Today

Aclaris Therapeutics (NASDAQ:ACRS) Now Covered by StockNews.com - Vimarsana News

Aclaris Therapeutics (NASDAQ:ACRS) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) in a research note issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock. A number of other research firms have also issued reports on ACRS. HC Wainwright reiterated a “buy” rating and set a […]

Investment Analysts' Weekly Ratings Updates for Aclaris Therapeutics (ACRS) - Vimarsana News

Investment Analysts' Weekly Ratings Updates for Aclaris Therapeutics (ACRS)

A number of firms have modified their ratings and price targets on shares of Aclaris Therapeutics (NASDAQ: ACRS) recently: 10/4/2023 – Aclaris Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock. 10/3/2023 – Aclaris Therapeutics is now covered by analysts at Evercore ISI. […]

PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday - Vimarsana News

PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s sess...

Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - Vimarsana News

Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) released its earnings results on Monday. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02, Briefing.com reports. Aclaris Therapeutics had a negative net margin of 292.11% and a negative return on equity of 41.71%. The firm had revenue […]

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $32.00 Average Price Target from Analysts - Vimarsana News

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $32.00 Average Price Target from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) has been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year […]

Source: wkrb13.com